358 related articles for article (PubMed ID: 32161193)
1. C3a receptor blockade protects podocytes from injury in diabetic nephropathy.
Morigi M; Perico L; Corna D; Locatelli M; Cassis P; Carminati CE; Bolognini S; Zoja C; Remuzzi G; Benigni A; Buelli S
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161193
[TBL] [Abstract][Full Text] [Related]
2. Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome.
Buelli S; Locatelli M; Carminati CE; Corna D; Cerullo D; Imberti B; Perico L; Brigotti M; Abbate M; Zoja C; Benigni A; Remuzzi G; Morigi M
Cells; 2022 May; 11(11):. PubMed ID: 35681450
[TBL] [Abstract][Full Text] [Related]
3. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein inhibits C3a/C3aR-dependent podocyte autophagy in favor of diabetic kidney disease.
Zhang L; Li W; Gong M; Zhang Z; Xue X; Mao J; Zhang H; Li S; Liu X; Wu F; Shi J; Fu G
FASEB J; 2022 Jun; 36(6):e22332. PubMed ID: 35503088
[TBL] [Abstract][Full Text] [Related]
5. Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy.
Gao S; Cui Z; Zhao MH
J Am Soc Nephrol; 2022 Sep; 33(9):1742-1756. PubMed ID: 35777783
[TBL] [Abstract][Full Text] [Related]
6. Sustained activation of C3aR in a human podocyte line impairs the morphological maturation of the cells.
Zheng JM; Wang SS; Tian X; Che DJ
Mol Med Rep; 2020 Dec; 22(6):5326-5338. PubMed ID: 33174024
[TBL] [Abstract][Full Text] [Related]
7. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway.
Li L; Yin Q; Tang X; Bai L; Zhang J; Gou S; Zhu H; Cheng J; Fu P; Liu F
PLoS One; 2014; 9(11):e113639. PubMed ID: 25422985
[TBL] [Abstract][Full Text] [Related]
8. FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury.
Chen X; Liu W; Xiao J; Zhang Y; Chen Y; Luo C; Huang Q; Peng F; Gong W; Li S; He X; Zhuang Y; Wu N; Liu Y; Wang Y; Long H
FASEB J; 2020 Oct; 34(10):13300-13316. PubMed ID: 32786113
[TBL] [Abstract][Full Text] [Related]
9. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
10. A previously unrecognized role of C3a in proteinuric progressive nephropathy.
Morigi M; Locatelli M; Rota C; Buelli S; Corna D; Rizzo P; Abbate M; Conti D; Perico L; Longaretti L; Benigni A; Zoja C; Remuzzi G
Sci Rep; 2016 Jun; 6():28445. PubMed ID: 27345360
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of C3a receptor attenuates the development of diabetic nephropathy.
Li XQ; Chang DY; Chen M; Zhao MH
BMJ Open Diabetes Res Care; 2019; 7(1):e000817. PubMed ID: 31798904
[TBL] [Abstract][Full Text] [Related]
12. Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.
Locatelli M; Zoja C; Zanchi C; Corna D; Villa S; Bolognini S; Novelli R; Perico L; Remuzzi G; Benigni A; Cassis P
Sci Rep; 2020 May; 10(1):8418. PubMed ID: 32439965
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Hudkins KL; Wietecha TA; Steegh F; Alpers CE
Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
[TBL] [Abstract][Full Text] [Related]
15. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
[TBL] [Abstract][Full Text] [Related]
16. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
Shao X; Zhang X; Hu J; Gao T; Chen J; Xu C; Wei C
Exp Cell Res; 2020 Mar; 388(2):111849. PubMed ID: 31954110
[TBL] [Abstract][Full Text] [Related]
17. Podocyte RNF166 deficiency alleviates diabetic nephropathy by mitigating mitochondria impairment and apoptosis via regulation of CYLD signal.
Hongbo M; Yanjiao D; Shuo W; Kun S; Yanjie L; Mengmeng L
Biochem Biophys Res Commun; 2021 Mar; 545():46-53. PubMed ID: 33545631
[TBL] [Abstract][Full Text] [Related]
18. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
19. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
20. Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy.
Lin J; Shi Y; Peng H; Shen X; Thomas S; Wang Y; Truong LD; Dryer SE; Hu Z; Xu J
J Pathol; 2015 May; 236(1):30-40. PubMed ID: 25641678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
